Sebia receives U.S. FDA Clearance for the CAPILLARYS 3 DBS devices

Press release
Apr. 11, 2024

The next generation instrument for screening hemoglobin disorders in newborns.

Apr. 18, 2024 Apr. 20, 2024

Event
Torino, Italy

European Myeloma Network Meeting – EMN 2024

Sebia booth: #9

Learn more

Sebia receives U.S. FDA Clearance for the FLC Kappa & Lambda assays

Press release
Mar. 06, 2024

Expanding offering for Multiple Myeloma and AL Amyloidosis Testing.

How External Quality Assessment supports quality improvement in laboratory hemoglobinopathy diagnosis

Webinar
Feb. 19, 2024

Educational Workshop with Dr. Barbara De la Salle

Our complete product range

Instruments

From the lowest to the highest volumes, with standalone instruments, workcell configurations or directly integrated into lab track automation, Sebia will provide the right solution for each laboratory.

See all our instruments

Tests

From multiple myeloma to metabolic disorders, hemoglobinopathies and genetic diseases, Sebia’s portfolio is designed to address clinical needs and improve laboratory efficiency and safety.

See all our tests

Our solutions tailored for your needs

Software

The networked expert companion of all Sebia instruments.

clinical-care-powerful-tools

Sebia Lean Service

With a modular and scalable offer, Sebia Lean Service is designed to enhance the laboratory performance with customized product and management solutions.

Learn more

Sebia Academy

We aim to educate and share scientific and medical educational information with our customers all around the world.

Learn more

Sebia Service

We offer daily assistance for technical and scientific matters.

Learn more

Our key figures

+20 000
installed instruments worldwide
+120
countries covered
+1 000
employees worldwide
0
Sebia Capillary Electrophoresis Protein tests performed in the world from Jan 1st, 2022

Create your free account MySebia

Customize your viewing experience
Get access to exclusive events near you
Bookmark and keep all your resources in one place
Subscribe to specific newsletters and content